Data / Companies / ADPT
Adaptive Biotechnologies Corp.Nasdaq
ADPT-US · CIK 0001478320 · Biological Products, (No Diagnostic Substances)
Revenue by quarter
US$ · last 8Hover a column for its exact figure
$0$20M$40M$60M$80M$100M
Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
| Quarter | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $71.6M | -$39.8M | -0.25 |
| Q1 FY2026 | $70.9M | -$20.0M | -0.13 |
| Q4 FY2025 | $71.7M | -$13.6M | -0.09 |
| Q3 FY2025 | $94.0M | $9.5M | 0.06 |
Newest filings
All 160| Form | Filed | |
|---|---|---|
| 10-Q | 4 Aug 2026 | |
| 8-K | 29 Jul 2026 | |
| 8-K | 22 Jun 2026 | |
| 8-K | 15 Jun 2026 | |
| 8-K | 9 Jun 2026 | |
| 10-Q | 5 May 2026 | |
| 8-K | 5 May 2026 | |
| ARS | 24 Apr 2026 |
Description
- Ticker
- ADPT-US
- Exchange
- Nasdaq
- Index
- –
- Industry
- Biological Products, (No Diagnostic Substances)
- SIC division
- Manufacturing
- CIK
- 0001478320
- Fiscal year ends
- Dec
- Filings held
- 160 since 2009
- 8-K events
- 70
- Shares short
- 12.0M, 15 Oct 2026
Financial statements
The main lines of the income statement, balance sheet and cash flow, by year and by quarter. Each period opens its filing.
5 years · US$ millions
| Fiscal period | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Period ending | 31 Dec 2021 | 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
| Reported in | 10-K | 10-K | 10-K | 10-K | 10-K |
| Report filed | 15 Feb 2022 | 14 Feb 2023 | 29 Feb 2024 | 3 Mar 2025 | 26 Feb 2026 |
| Revenue | 154M | 185M | 170M | 179M | 277M |
| Cost of revenue | 49M | 58M | 76M | 72M | 71M |
| Gross profit | 105M | 127M | 95M | 107M | 206M |
| Gross margin | 68.1% | 68.7% | 55.6% | 59.7% | 74.2% |
| Research and development | 142M | 142M | 122M | 103M | 94M |
| Operating income | -209M | -200M | -227M | -163M | -57M |
| Operating margin | -135.4% | -108.0% | -133.3% | -90.8% | -20.6% |
| Profit before tax | -207M | -200M | -225M | -160M | -59M |
| Income tax | – | – | 0M | 0M | 0M |
| Net income | -207M | -200M | -225M | -159M | -59M |
| Net margin | -134.3% | -108.0% | -132.3% | -89.1% | -21.5% |
| Earnings per share, diluted | -1.48 | -1.40 | -1.56 | -1.08 | -0.39 |
| Diluted shares | 140M | 143M | 144M | 147M | 152M |
Showing the last 5 years, FY2021 onwards. The full record goes back to FY2017 and comes with a data plan. Tell us what you need
Ratios
Worked out the same way for every company. Hover a ratio for how it is calculated.
Valuation
- Market cap
- $4.4B
- Price
- $27.66
- Price to book
- 30.78×
- Enterprise value
- $4.6B
- Market cap / sales
- 14.28×
- 52-week high
- $29.86
- 52-week low
- $12.41
Profitability
- Gross margin, TTM
- 75.6%
- Operating margin
- -12.2%
- Net margin
- -20.7%
- FCF margin
- -7.8%
- ROE
- -44.7%
- ROE, 3-year average
- -59.6%
- ROCE
- -7.8%
- Interest cover
- -3.25×
Growth
- Sales growth, TTM
- 50.1%
- Sales CAGR, 3 years
- 14.3%
- Sales CAGR, 5 years
- 23.0%
- Price, 1 year
- 61.6%
- Price CAGR, 3 years
- 86.7%
- Price CAGR, 5 years
- -4.4%
Balance sheet
- Cash and equivalents
- $169.9M
- Borrowings
- $334.9M
- Net debt
- $165.0M
- Debt to equity
- 2.34×
- Shareholders' equity
- $142.9M
- Total assets
- $640.7M
- Net debt change, 1 year
- $74.6M
Shareholders
- Shares outstanding
- 159,059,622
- Share count, last 12 months
- 4.5%
- Years FCF margin > 20%, of 5
- 0
Showing the last 5 years, FY2021 onwards. The full record goes back to FY2017 and comes with a data plan. Tell us what you need
What the company said with its results
The key points, guidance and management's own words from each of the last four results releases.
No results summary read for this company yet.
Revenue by segment
As the company reports it in the segment note of each annual report: by business, by product and by region, latest year.
By business, FY2025
- MRD$212.3M 76.7%
- IM$64.6M 23.3%
3 years held, FY2023 to FY2025
Showing the last 5 years, FY2021 onwards. The full record goes back to FY2017 and comes with a data plan. Tell us what you need
Company events
Every 8-K, sorted by the event it reports, with the moment the SEC accepted it in New York time.
| 29 Jul 2026 | 8-K | ResultsLeadership change | 2.02, 5.02, 9.01 | |
| 22 Jun 2026 | 8-K | Material agreementAgreement endedNew debtShare saleOther events | 1.01, 1.02, 2.03, 3.02, 8.01, 9.01 | |
| 15 Jun 2026 | 8-K | Other events | 8.01, 9.01 | |
| 9 Jun 2026 | 8-K | Shareholder vote | 5.07 | |
| 5 May 2026 | 8-K | Results | 2.02, 9.01 | |
| 5 Feb 2026 | 8-K | Results | 2.02, 9.01 | |
| 12 Jan 2026 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 30 Dec 2025 | 8-K | Other events | 8.01 | |
| 5 Nov 2025 | 8-K | Results | 2.02, 9.01 | |
| 18 Aug 2025 | 8-K | Agreement ended | 1.02 | |
| 5 Aug 2025 | 8-K | Results | 2.02, 9.01 | |
| 12 Jun 2025 | 8-K | Shareholder vote | 5.07 | |
| 1 May 2025 | 8-K | Results | 2.02, 9.01 | |
| 11 Feb 2025 | 8-K | Results | 2.02, 9.01 | |
| 7 Nov 2024 | 8-K | Results | 2.02, 9.01 | |
| 1 Aug 2024 | 8-K | Results | 2.02, 9.01 | |
| 11 Jun 2024 | 8-K | Shareholder voteOther events | 5.07, 8.01 | |
| 7 May 2024 | 8-K | Results | 2.02, 9.01 | |
| 9 Apr 2024 | 8-K | Leadership change | 5.02, 9.01 | |
| 5 Apr 2024 | 8-K | Results | 2.02, 9.01 | |
| 2 Apr 2024 | 8-K | Leadership change | 5.02 | |
| 14 Feb 2024 | 8-K | Results | 2.02, 9.01 | |
| 9 Nov 2023 | 8-K | Results | 2.02, 9.01 | |
| 1 Sep 2023 | 8-K | Leadership change | 5.02 | |
| 2 Aug 2023 | 8-K | ResultsLeadership change | 2.02, 5.02, 9.01 | |
| 3 Jul 2023 | 8-K | Delisting notice | 3.01 | |
| 13 Jun 2023 | 8-K | Leadership changeShareholder vote | 5.02, 5.07 | |
| 9 May 2023 | 8-K | Investor updateOther events | 7.01, 8.01, 9.01 | |
| 3 May 2023 | 8-K | Results | 2.02, 9.01 | |
| 11 Apr 2023 | 8-K | Leadership change | 5.02 | |
| 14 Feb 2023 | 8-K | Results | 2.02, 9.01 | |
| 3 Nov 2022 | 8-K | Results | 2.02, 9.01 | |
| 12 Sep 2022 | 8-K | Material agreementNew debtOther events | 1.01, 2.03, 8.01, 9.01 | |
| 3 Aug 2022 | 8-K | Results | 2.02, 9.01 | |
| 14 Jun 2022 | 8-K | Shareholder vote | 5.07 | |
| 4 May 2022 | 8-K | Results | 2.02, 9.01 | |
| 25 Mar 2022 | 8-K | Other events | 8.01 | |
| 11 Mar 2022 | 8-K | Leadership change | 5.02 | |
| 15 Feb 2022 | 8-K | ResultsLeadership change | 2.02, 5.02, 9.01 | |
| 10 Jan 2022 | 8-K | ResultsLeadership change | 2.02, 5.02, 9.01 | |
| 3 Nov 2021 | 8-K | ResultsLeadership change | 2.02, 5.02, 9.01 | |
| 4 Aug 2021 | 8-K | Results | 2.02, 9.01 | |
| 14 Jun 2021 | 8-K | Shareholder vote | 5.07 | |
| 5 May 2021 | 8-K | Results | 2.02, 9.01 | |
| 17 Mar 2021 | 8-K | Leadership changeInvestor update | 5.02, 7.01, 9.01 | |
| 5 Mar 2021 | 8-K | Leadership change | 5.02 | |
| 2 Mar 2021 | 8-K | Investor updateOther events | 7.01, 8.01 | |
| 24 Feb 2021 | 8-K | Results | 2.02, 9.01 | |
| 27 Jan 2021 | 8-K | Leadership change | 5.02 | |
| 12 Nov 2020 | 8-K | Other events | 8.01 |
1–50 of 70
8-K events each year
Hover a column for its exact count
051015
'19'23'26
Every filing
The company's filings with the SEC, newest first: 160 held. Insider, fund and large-holder filings have their own tables below.
| 4 Aug 2026 | 10-Q | 30 Jun 2026 | |
| 29 Jul 2026 | 8-K | 24 Jul 2026 | |
| 22 Jun 2026 | 8-K | 15 Jun 2026 | |
| 15 Jun 2026 | 8-K | 15 Jun 2026 | |
| 9 Jun 2026 | 8-K | 5 Jun 2026 | |
| 5 May 2026 | 10-Q | 31 Mar 2026 | |
| 5 May 2026 | 8-K | 5 May 2026 | |
| 24 Apr 2026 | ARS | 31 Dec 2025 | |
| 24 Apr 2026 | DEFA14A | – | |
| 24 Apr 2026 | DEF 14A | 5 Jun 2026 | |
| 27 Feb 2026 | S-8 | – | |
| 26 Feb 2026 | 10-K | 31 Dec 2025 | |
| 5 Feb 2026 | 8-K | 5 Feb 2026 | |
| 12 Jan 2026 | 8-K | 12 Jan 2026 | |
| 30 Dec 2025 | 8-K | 30 Dec 2025 | |
| 5 Nov 2025 | 10-Q | 30 Sep 2025 | |
| 5 Nov 2025 | 8-K | 5 Nov 2025 | |
| 18 Aug 2025 | 8-K | 13 Aug 2025 | |
| 5 Aug 2025 | 10-Q | 30 Jun 2025 | |
| 5 Aug 2025 | 8-K | 5 Aug 2025 | |
| 12 Jun 2025 | 8-K | 10 Jun 2025 | |
| 1 May 2025 | 10-Q | 31 Mar 2025 | |
| 1 May 2025 | 8-K | 1 May 2025 | |
| 29 Apr 2025 | ARS | 31 Dec 2024 | |
| 29 Apr 2025 | DEFA14A | – | |
| 29 Apr 2025 | DEF 14A | 10 Jun 2025 | |
| 3 Mar 2025 | 10-K | 31 Dec 2024 | |
| 11 Feb 2025 | 8-K | 11 Feb 2025 | |
| 7 Nov 2024 | 10-Q | 30 Sep 2024 | |
| 7 Nov 2024 | 8-K | 7 Nov 2024 | |
| 1 Aug 2024 | 10-Q | 30 Jun 2024 | |
| 1 Aug 2024 | 8-K | 1 Aug 2024 | |
| 11 Jun 2024 | 8-K | 7 Jun 2024 | |
| 24 May 2024 | DEFA14A | – | |
| 7 May 2024 | 10-Q | 31 Mar 2024 | |
| 7 May 2024 | 8-K | 7 May 2024 | |
| 26 Apr 2024 | ARS | 31 Dec 2023 | |
| 26 Apr 2024 | DEFA14A | – | |
| 26 Apr 2024 | DEF 14A | 7 Jun 2024 | |
| 9 Apr 2024 | 8-K | 4 Apr 2024 | |
| 5 Apr 2024 | 8-K | 2 Apr 2024 | |
| 2 Apr 2024 | 8-K | 1 Apr 2024 | |
| 29 Feb 2024 | 10-K | 31 Dec 2023 | |
| 14 Feb 2024 | 8-K | 14 Feb 2024 | |
| 9 Nov 2023 | 10-Q | 30 Sep 2023 | |
| 9 Nov 2023 | 8-K | 9 Nov 2023 | |
| 1 Sep 2023 | 8-K | 1 Sep 2023 | |
| 2 Aug 2023 | 10-Q | 30 Jun 2023 | |
| 2 Aug 2023 | 8-K | 28 Jul 2023 | |
| 3 Jul 2023 | 8-K | 26 Jun 2023 |
1–50 of 150
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months, with the shares they held after.
| 26 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 8,503 | $25.94 | $220.6K | 381,180 | 26 Oct 2026 |
| 26 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 3,378 | $26.30 | $88.8K | 377,802 | 26 Oct 2026 |
| 23 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 4,500 | $24.50 | $110.3K | 385,183 | 26 Oct 2026 |
| 23 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 7,381 | $25.28 | $186.6K | 377,802 | 26 Oct 2026 |
| 22 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 10,181 | $24.38 | $248.2K | 379,502 | 26 Oct 2026 |
| 22 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 1,700 | $25.29 | $43.0K | 377,802 | 26 Oct 2026 |
| 21 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 5,999 | $25.25 | $151.5K | 383,684 | 21 Oct 2026 |
| 21 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 5,882 | $25.57 | $150.4K | 377,802 | 21 Oct 2026 |
| 20 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 11,781 | $24.53 | $289.0K | 377,902 | 21 Oct 2026 |
| 20 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 100 | $24.85 | $2.5K | 377,802 | 21 Oct 2026 |
| 19 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 11,881 | $24.05 | $285.7K | 377,802 | 21 Oct 2026 |
| 16 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 11,581 | $24.21 | $280.4K | 378,102 | 16 Oct 2026 |
| 16 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 300 | $25.45 | $7.6K | 377,802 | 16 Oct 2026 |
| 15 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 11,881 | $25.61 | $304.3K | 377,802 | 16 Oct 2026 |
| 14 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 6,781 | $25.57 | $173.4K | 382,902 | 16 Oct 2026 |
| 14 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 5,100 | $25.82 | $131.7K | 377,802 | 16 Oct 2026 |
| 13 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 11,881 | $25.50 | $303.0K | 377,802 | 13 Oct 2026 |
| 12 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 9,181 | $25.35 | $232.7K | 380,502 | 13 Oct 2026 |
| 12 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 2,700 | $26.07 | $70.4K | 377,802 | 13 Oct 2026 |
| 9 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 11,881 | $26.41 | $313.8K | 377,802 | 13 Oct 2026 |
| 8 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 11,881 | $25.66 | $304.9K | 377,802 | 8 Oct 2026 |
| 7 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 11,881 | $26.40 | $313.7K | 377,802 | 8 Oct 2026 |
| 6 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 9,381 | $27.36 | $256.7K | 380,302 | 8 Oct 2026 |
| 6 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 1,100 | $28.21 | $31.0K | 379,202 | 8 Oct 2026 |
| 6 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 901 | $29.71 | $26.8K | 378,301 | 8 Oct 2026 |
| 6 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 499 | $30.53 | $15.2K | 377,802 | 8 Oct 2026 |
| 6 Oct 2026 | Bobulsky SusanChief Commercial Officer, MRD | Sale under a trading plan | 6,444 | $30.00 | $193.3K | 389,350 | 8 Oct 2026 |
| 5 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 6,699 | $28.82 | $193.1K | 382,984 | 5 Oct 2026 |
| 5 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 5,182 | $29.67 | $153.8K | 377,802 | 5 Oct 2026 |
| 2 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 11,881 | $28.13 | $334.2K | 377,802 | 5 Oct 2026 |
| 1 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 6,081 | $27.57 | $167.7K | 383,602 | 5 Oct 2026 |
| 1 Oct 2026 | Rubinstein JuliePresident and COO | Sale under a trading plan | 5,800 | $28.56 | $165.6K | 377,802 | 5 Oct 2026 |
| 1 Oct 2026 | Lo FrancisChief People Officer | Sale under a trading plan | 8,094 | $27.52 | $222.7K | 239,565 | 5 Oct 2026 |
| 1 Oct 2026 | Lo FrancisChief People Officer | Sale under a trading plan | 18,698 | $28.61 | $535.0K | 220,867 | 5 Oct 2026 |
| 16 Sep 2026 | Lo FrancisChief People Officer | Sale under a trading plan | 107,537 | $28.02 | $3.0M | 228,736 | 18 Sep 2026 |
| 16 Sep 2026 | Lo FrancisChief People Officer | Sale under a trading plan | 7,869 | $28.57 | $224.8K | 220,867 | 18 Sep 2026 |
| 15 Sep 2026 | Bobulsky SusanChief Commercial Officer, MRD | Sale under a trading plan | 1,195 | $27.00 | $32.3K | 395,794 | 17 Sep 2026 |
| 26 Aug 2026 | Owen Katey EinterzDirector | Sale outside a trading plan | 9,615 | $26.00 | $250.0K | 78,639 | 28 Aug 2026 |
| 18 Aug 2026 | Hershberg RobertDirector | Sale outside a trading plan | 15,000 | $24.39 | $365.9K | 62,347 | 20 Aug 2026 |
| 18 Aug 2026 | Hershberg RobertDirector | Sale outside a trading plan | 15,664 | $24.41 | $382.4K | 46,683 | 20 Aug 2026 |
| 18 Aug 2026 | Robins Chad MCEO and Chairman | Sale outside a trading plan | 278,472 | $24.48 | $6.8M | 2,180,722 | 19 Aug 2026 |
| 18 Aug 2026 | Robins Chad MCEO and Chairman | Sale outside a trading plan | 204 | $25.14 | $5.1K | 2,180,518 | 19 Aug 2026 |
| 17 Aug 2026 | Robins Chad MCEO and Chairman | Sale outside a trading plan | 318,799 | $25.08 | $8.0M | 2,183,043 | 19 Aug 2026 |
| 17 Aug 2026 | Robins Chad MCEO and Chairman | Sale outside a trading plan | 2,525 | $25.57 | $64.6K | 2,180,518 | 19 Aug 2026 |
| 17 Aug 2026 | Neupert Peter MDirector | Sale outside a trading plan | 15,000 | $25.23 | $378.4K | 240,315 | 19 Aug 2026 |
| 17 Aug 2026 | Neupert Peter MDirector | Sale outside a trading plan | 40,000 | $25.10 | $1.0M | 200,315 | 19 Aug 2026 |
| 17 Aug 2026 | Neupert Peter MDirector | Sale outside a trading plan | 69,690 | $25.16 | $1.8M | 130,625 | 19 Aug 2026 |
| 10 Aug 2026 | Bobulsky SusanChief Commercial Officer, MRD | Sale under a trading plan | 3,000 | $25.00 | $75.0K | 396,989 | 12 Aug 2026 |
| 30 Jul 2026 | Bobulsky SusanChief Commercial Officer, MRD | Sale under a trading plan | 1,299 | $24.00 | $31.2K | 399,989 | 3 Aug 2026 |
| 21 Jul 2026 | Robins Harlan SChief Scientific Officer | Sale under a trading plan | 278,698 | $21.72 | $6.1M | 1,025,760 | 23 Jul 2026 |
1–50 of 150
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| 6 Oct 2026 | SUSAN BOBULSKYOfficer | 6,444 | $192.3K | 6 Oct 2026 |
| 1 Oct 2026 | JULIE RUBINSTEINOfficer | 379,777 | $11.0M | 1 Oct 2026 |
| 16 Sep 2026 | FRANCIS LOOfficer | 142,198 | $3.8M | 16 Sep 2026 |
| 15 Sep 2026 | SUSAN BOBULSKYOfficer | 1,195 | $29.6K | 15 Sep 2026 |
| 26 Aug 2026 | KATHERINE E OWENDirector | 9,615 | $250.0K | 26 Aug 2026 |
| 20 Aug 2026 | Harlan RobinsFormer Officer | 402,160 | $10.2M | 20 Aug 2026 |
| 19 Aug 2026 | Harlan RobinsFormer Officer | 215,632 | $5.5M | 19 Aug 2026 |
| 18 Aug 2026 | ROBERT M HERSHBERGDirector | 30,664 | $748.3K | 18 Aug 2026 |
| 18 Aug 2026 | Harlan RobinsFormer Officer | 261,044 | $6.4M | 18 Aug 2026 |
| 18 Aug 2026 | Chad RobinsOfficer | 278,676 | $6.8M | 18 Aug 2026 |
| 17 Aug 2026 | PETER NEUPERTDirector | 124,690 | $3.1M | 17 Aug 2026 |
| 17 Aug 2026 | Harlan RobinsFormer Officer | 300,992 | $7.5M | 17 Aug 2026 |
| 17 Aug 2026 | Chad RobinsOfficer | 321,324 | $8.0M | 17 Aug 2026 |
| 10 Aug 2026 | SUSAN BOBULSKYOfficer | 3,000 | $74.8K | 10 Aug 2026 |
| 30 Jul 2026 | SUSAN BOBULSKYOfficer | 1,299 | $29.3K | 30 Jul 2026 |
| 21 Jul 2026 | Harlan RobinsOfficer | 492,400 | $11.1M | 21 Jul 2026 |
| 16 Jul 2026 | SUSAN BOBULSKYOfficer | 5,000 | $114.5K | 16 Jul 2026 |
| 2 Jul 2026 | Harlan RobinsOfficer | 386,240 | $8.2M | 2 Jul 2026 |
| 1 Jul 2026 | SUSAN BOBULSKYOfficer | 487 | $10.4K | 1 Jul 2026 |
| 1 Jul 2026 | FRANCIS LOOfficer | 199,260 | $4.3M | 1 Jul 2026 |
| 29 Jun 2026 | SHARON BENZENOOfficer | 152,931 | $3.2M | 29 Jun 2026 |
| 26 Jun 2026 | SHARON BENZENOOfficer | 12,871 | $260.6K | 26 Jun 2026 |
| 25 Jun 2026 | SUSAN BOBULSKYOfficer | 5,000 | $96.7K | 25 Jun 2026 |
| 25 Jun 2026 | MICHELLE GRIFFINDirector | 52,084 | $1.0M | 25 Jun 2026 |
| 16 Jun 2026 | Harlan RobinsOfficer | 6,160 | $106.1K | 16 Jun 2026 |
| 15 Jun 2026 | Harlan RobinsOfficer | 100,000 | $1.7M | 15 Jun 2026 |
| 11 Jun 2026 | SUSAN BOBULSKYOfficer | 5,000 | $85.3K | 11 Jun 2026 |
| 4 Jun 2026 | SUSAN BOBULSKYOfficer | 11,000 | $175.9K | 4 Jun 2026 |
| 4 Jun 2026 | FRANCIS LOOfficer | 42,085 | $672.9K | 4 Jun 2026 |
| 15 May 2026 | PISKEL KYLEOfficer | 3,160 | $40.5K | 18 May 2026 |
| 8 Apr 2026 | Harlan RobinsOfficer | 10,000 | $148.4K | 8 Apr 2026 |
| 8 Apr 2026 | FRANCIS LOOfficer | 22,564 | $309.4K | 8 Apr 2026 |
| 8 Apr 2026 | Chad RobinsOfficer | 37,263 | $553.0K | 8 Apr 2026 |
| 6 Apr 2026 | Chad RobinsOfficer | 83,332 | $1.2M | 6 Apr 2026 |
| 16 Mar 2026 | PISKEL KYLEOfficer | 18,672 | $271.1K | 11 Mar 2026 |
| 16 Mar 2026 | BOBULSKY SUSANOfficer | 41,338 | $600.2K | 11 Mar 2026 |
| 16 Mar 2026 | BENZENO SHARONOfficer | 63,103 | $916.3K | 11 Mar 2026 |
| 16 Mar 2026 | RUBINSTEIN JULIEOfficer | 122,523 | $1.8M | 11 Mar 2026 |
| 16 Mar 2026 | ROBINS CHAD MOfficer, Director | 470,167 | $6.8M | 11 Mar 2026 |
| 16 Mar 2026 | ROBINS HARLAN SOfficer | 470,266 | $6.8M | 11 Mar 2026 |
| 11 Mar 2026 | MICHELLE GRIFFINDirector | 15,394 | $214.1K | 11 Mar 2026 |
| 11 Mar 2026 | FRANCIS LOOfficer | 30,593 | $444.2K | 11 Mar 2026 |
| 10 Mar 2026 | LO FRANCISOfficer | 38,074 | $625.9K | 5 Mar 2026 |
| 3 Mar 2026 | Harlan RobinsOfficer | 14,233 | $228.9K | 3 Mar 2026 |
| 3 Mar 2026 | MICHELLE GRIFFINDirector | 48,044 | $774.5K | 3 Mar 2026 |
| 3 Mar 2026 | Chad RobinsOfficer | 53,083 | $853.6K | 3 Mar 2026 |
| 3 Mar 2026 | JULIE RUBINSTEINOfficer | 1,206,661 | $19.5M | 3 Mar 2026 |
| 2 Mar 2026 | Harlan RobinsOfficer | 10,000 | $161.2K | 2 Mar 2026 |
| 2 Mar 2026 | Chad RobinsOfficer | 289,024 | $4.7M | 2 Mar 2026 |
| 27 Feb 2026 | Chad RobinsOfficer | 182,891 | $2.9M | 27 Feb 2026 |
1–50 of 72
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| 15 May 2026 | VIKING GLOBAL INVESTORS LP | 13G amended | 18.8% | 30.0M |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 21 Jan 2026 | BlackRock, Inc. | 13G amended | 7.9% | 12.0M |
Trades by members of the House
From each member's periodic transaction report: the amount is the band the report gives.
No House trades in this company.
Short interest
Shares sold short and not yet bought back, on every FINRA settlement date.
Shares short, each settlement
| 15 Oct 2026 | 12.0M | +1.25% | 5.03 |
| 30 Sep 2026 | 11.8M | -12.2% | 4.43 |
| 15 Sep 2026 | 13.5M | +15.17% | 7.89 |
| 31 Aug 2026 | 11.7M | -12.09% | 6.37 |
| 14 Aug 2026 | 13.3M | +6.67% | 5.72 |
| 31 Jul 2026 | 12.5M | +9.6% | 4.39 |
| 15 Jul 2026 | 11.4M | +0.38% | 4.31 |
| 30 Jun 2026 | 11.4M | +48.5% | 2.23 |
| 15 Jun 2026 | 7.6M | -7.23% | 2.82 |
| 29 May 2026 | 8.2M | -7.38% | 5.13 |
1–10 of 138
Funds that hold it
Every fund's holding from its latest Form 13F, largest first, with what it added or trimmed in the quarter.
Funds holding
342
quarter to 30 Jun 2026
Added or new
151
since 31 Mar 2026
Trimmed
88
in the quarter
Largest holder
Viking Global Investors LP
$643.4M
The 60 largest of 342 funds, by value
| Viking Global Investors LP | $643.4M | 30.0M | 0 | Held | 1.83% | Filing ↗ |
| BlackRock, Inc. | $324.7M | 15.1M | +1.8M | Added | 0.01% | Filing ↗ |
| Vanguard Capital Management LLC | $137.4M | 6.4M | +309.4K | Added | 0.00% | Filing ↗ |
| Wellington Management Group LLP | $126.8M | 5.9M | +2.1M | Added | 0.02% | Filing ↗ |
| Vanguard Portfolio Management LLC | $117.5M | 5.5M | +984.8K | Added | 0.01% | Filing ↗ |
| D. E. Shaw & Co., Inc. | $99.2M | 4.6M | +2.7M | Added | 0.06% | Filing ↗ |
| Westfield Capital Management Co. LP | $91.5M | 4.3M | -1.2M | Trimmed | 0.30% | Filing ↗ |
| Geode Capital Management, LLC | $78.1M | 3.6M | +5.8K | Added | 0.00% | Filing ↗ |
| State Street Corp. | $74.2M | 3.5M | +231.1K | Added | 0.00% | Filing ↗ |
| Invesco Ltd. | $66.4M | 3.1M | -1.4M | Trimmed | 0.01% | Filing ↗ |
| Goldman Sachs Group Inc. | $64.0M | 3.0M | -257.9K | Trimmed | 0.01% | Filing ↗ |
| Price T Rowe Associates Inc. | $57.2M | 2.7M | +1.1M | Added | 0.01% | Filing ↗ |
| Driehaus Capital Management LLC | $54.2M | 2.5M | +777.1K | Added | 0.31% | Filing ↗ |
| Arrowstreet Capital, Limited Partnership | $54.2M | 2.5M | +529.4K | Added | 0.02% | Filing ↗ |
| Lord, Abbett & Co. LLC | $53.1M | 2.5M | -1.1M | Trimmed | 0.16% | Filing ↗ |
| Nuveen, LLC | $50.8M | 2.4M | +1.1M | Added | 0.01% | Filing ↗ |
| BNP Paribas Asset Management Holding S.A. | $46.8M | 2.2M | -505.8K | Trimmed | 0.05% | Filing ↗ |
| Fred Alger Management, LLC | $44.9M | 2.1M | +29.1K | Added | 0.15% | Filing ↗ |
| ARK Investment Management LLC | $44.8M | 2.1M | -2.7K | Trimmed | 0.29% | Filing ↗ |
| Nomura Asset Management International Inc. | $40.5M | 1.9M | +8.0K | Added | 0.06% | Filing ↗ |
| Aristotle Atlantic Partners, LLC | $39.4M | 1.8M | +124.2K | Added | 1.64% | Filing ↗ |
| T. Rowe Price Investment Management, Inc. | $38.2M | 1.8M | +860.4K | Added | 0.03% | Filing ↗ |
| Bank of America Corp. | $37.1M | 1.7M | +502.1K | Added | 0.00% | Filing ↗ |
| Jane Street Group, LLC | $34.1M | 1.6M | +908.3K | Added | 0.02% | Filing ↗ |
| Northern Trust Corp. | $32.3M | 1.5M | +115.0K | Added | 0.00% | Filing ↗ |
| Sumitomo Mitsui Trust Group, Inc. | $28.5M | 1.3M | -265.5K | Trimmed | 0.02% | Filing ↗ |
| Amova Asset Management Americas, Inc. | $28.5M | 1.3M | -265.5K | Trimmed | 0.37% | Filing ↗ |
| Oberweis Asset Management Inc. | $27.0M | 1.3M | +451.8K | Added | 0.56% | Filing ↗ |
| Perceptive Advisors LLC | $26.1M | 1.2M | +1.1M | Added | 0.41% | Filing ↗ |
| Charles Schwab Investment Management Inc. | $25.3M | 1.2M | +32.9K | Added | 0.00% | Filing ↗ |
| Ameriprise Financial Inc. | $23.3M | 1.1M | -1.9M | Trimmed | 0.01% | Filing ↗ |
| Massachusetts Financial Services Co. | $23.0M | 1.1M | -396 | Held | 0.01% | Filing ↗ |
| Blue Water Life Science Advisors, LP | $21.7M | 1.0M | 0 | Held | 13.65% | Filing ↗ |
| Vanguard Fiduciary Trust Co. | $20.0M | 934.7K | +63.8K | Added | 0.00% | Filing ↗ |
| Aberdeen Group plc | $19.7M | 919.0K | -151.6K | Trimmed | 0.03% | Filing ↗ |
| Freestone Grove Partners LP | $18.9M | 881.7K | +881.7K | New | 0.12% | Filing ↗ |
| Kennedy Capital Management LLC | $18.2M | 849.8K | -81.7K | Trimmed | 0.32% | Filing ↗ |
| HRT Financial LP | $17.1M | 795.2K | +663.9K | Added | 0.03% | Filing ↗ |
| Connor, Clark & Lunn Investment Management Ltd. | $16.9M | 785.9K | +136.3K | Added | 0.03% | Filing ↗ |
| Panagora Asset Management Inc. | $16.7M | 777.6K | +261.7K | Added | 0.05% | Filing ↗ |
| Morgan Stanley | $16.4M | 766.2K | -200.9K | Trimmed | 0.00% | Filing ↗ |
| Granite Investment Partners, LLC | $16.2M | 757.2K | +257.2K | Added | 0.83% | Filing ↗ |
| Trexquant Investment LP | $15.8M | 736.3K | +164.7K | Added | 0.10% | Filing ↗ |
| FMR LLC | $15.2M | 709.5K | +142.5K | Added | 0.00% | Filing ↗ |
| Jennison Associates LLC | $14.7M | 686.2K | -66.9K | Trimmed | 0.01% | Filing ↗ |
| Hillsdale Investment Management Inc. | $14.7M | 684.2K | +59.0K | Added | 0.34% | Filing ↗ |
| Next Century Growth Investors LLC | $13.1M | 609.8K | +105.5K | Added | 0.69% | Filing ↗ |
| Wasatch Advisors LP | $12.4M | 576.3K | +576.3K | New | 0.08% | Filing ↗ |
| Tudor Investment Corp. Et Al | $11.7M | 543.5K | -242.8K | Trimmed | 0.05% | Filing ↗ |
| ExodusPoint Capital Management, LP | $11.1M | 518.1K | -36.9K | Trimmed | 0.10% | Filing ↗ |
1–50 of 60
Dividends and buybacks
Dividend per share, the cash paid and the shares bought back, each fiscal year.
This company has paid no dividend in the years held.
Peers
Companies in the same industry, largest first, on the same measures.
| Company | Market value | Revenue, 12 months | Revenue growth | Operating margin | Net margin | ROE | P/E | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corp.this company | $4.4B | $308.1M | 50.1% | -12.2% | -20.7% | -44.7% | – | – |
| Amgen Inc. | $242.2B | $38.1B | 9.1% | 30.0% | 23.0% | 74.8% | 27.8× | 20.2× |
| Gilead Sciences, Inc. | $197.4B | $30.5B | 5.5% | -8.2% | -10.6% | -27.4% | – | – |
| Moderna, Inc. | $82.9B | $2.2B | -27.6% | -149.0% | -141.4% | -46.6% | – | – |
| argenx SE | $54.6B | $4.2B | 89.9% | – | – | 17.6% | 45.1× | – |
| Biogen Inc. | $37.3B | $10.0B | 0.3% | 10.1% | 8.3% | 4.4% | 44.7× | 23.8× |
| BioNTech SE | $21.9B | $3.2B | 4.3% | -49.0% | -39.6% | -5.9% | – | – |
| Exelixis, Inc. | $16.3B | $2.4B | 9.2% | 39.9% | 35.3% | 46.7% | 20.6× | 16.0× |
| Neurocrine Biosciences Inc. | $14.8B | $3.4B | 34.4% | 23.6% | 20.9% | 19.1% | 21.4× | 17.2× |
| Halozyme Therapeutics, Inc. | $14.7B | $1.7B | 41.2% | 35.9% | 24.9% | 288.1% | 38.4× | 27.2× |
| Bio-Techne Corp. | $11.3B | $1.2B | -0.4% | 20.7% | 15.0% | 8.6% | 63.1× | 32.3× |
What the company does
The description for this company is being written.
Free for your personal research, with credit and a link. For API access, bulk files or commercial use, tell us what you need. The data licence